24 December 2008 -- AstraZeneca today announced the company has received a Complete Response Letter from the U.S. FDA asking for additional information for the supplemental New Drug Application for SEROQUEL XR (quetiapine fumarate) Extended Release Tablets for the treatment of Major Depressive Disorder (MDD) in adult patients.
The details can be read here.
No comments:
Post a Comment